Invivyd (IVVD) to Release Quarterly Earnings on Thursday

Invivyd (NASDAQ:IVVD) is expected to be releasing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Invivyd to announce earnings of ($0.15) per share and revenue of $14.4010 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 19, 2026 at 9:30 AM ET.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.05). The company had revenue of $13.74 million during the quarter, compared to analysts’ expectations of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. On average, analysts expect Invivyd to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Invivyd Price Performance

NASDAQ IVVD opened at $0.67 on Tuesday. The company has a fifty day moving average of $0.81 and a 200 day moving average of $1.29. The company has a market capitalization of $198.30 million, a PE ratio of -2.17 and a beta of 0.71. Invivyd has a 1 year low of $0.48 and a 1 year high of $3.07.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on IVVD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research note on Friday, July 24th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Invivyd in a research note on Monday, June 15th. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Hedge Funds Weigh In On Invivyd

Several hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new stake in Invivyd during the third quarter worth approximately $18,831,000. ADAR1 Capital Management LLC purchased a new position in Invivyd during the 3rd quarter worth approximately $8,108,000. Janus Henderson Group PLC increased its position in Invivyd by 28.2% during the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after buying an additional 7,160,065 shares during the period. State Street Corp increased its position in Invivyd by 1,636.7% during the fourth quarter. State Street Corp now owns 5,637,593 shares of the company’s stock worth $13,925,000 after buying an additional 5,312,986 shares during the period. Finally, Siren L.L.C. purchased a new stake in Invivyd in the fourth quarter valued at approximately $9,880,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.